Table 1.
Demographic and baseline clinical characteristics
| Dexmedetomidine | Propofol | P value | |
|---|---|---|---|
| n | 30 | 33 | |
| Age* | 58.76 ± 15.09 | 62.96 ± 9.69 | 0.19 |
| Male gender | 13 (43.3) | 23 (69.7) | 0.03 |
| Weight* | 76.43 ± 18.99 | 75.73 ± 15.44 | 0.87 |
| ASA score* | 2 (2–2) | 2 (2–3) | 0.47 |
| Baseline CO2* | 35.27 ± 9.20 | 37.40 ± 8.66 | 0.41 |
| COPD | 6 | 8 | 0.86 |
| IHD | 1 | 3 | 0.38 |
| CHF | 0 | 2 (6.3) | 0.30 |
| neuro-psychiatric medication# | 3 | 0 | 0.16 |
| Procedure type | |||
| BAL | 9 | 5 | 0.55 |
| Bronchoscopy + TBB | 7 | 9 | |
| Bronchoscopy + Cryo TBB | 6 | 5 | |
| EBUS | 5 | 9 | |
| Laser/balloon dilation | 3 | 5 |
ASA – American Society of Anesthesiologists; BAL – bronchoalveolar lavage; TBB – transbronchial biopsy; EBUS – endobronchial ultrasound; COPD – chronic obstructive pulmonary disease; IHD – ischemic heart disease; CHF – chronic heart failure
*Data presented in mean ± SD or median + IQR
#Antiepileptic drugs, Psychotropic Drugs